ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) is expected to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect ArriVent BioPharma to post earnings of ($0.88) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, analysts expect ArriVent BioPharma to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Up 3.7%

Shares of AVBP traded up $1.11 during mid-day trading on Monday, hitting $31.10. The company’s stock had a trading volume of 58,337 shares, compared to its average volume of 497,838. The firm has a 50-day simple moving average of $25.52 and a 200 day simple moving average of $22.81. The firm has a market capitalization of $1.44 billion, a P/E ratio of -7.05 and a beta of 1.51. ArriVent BioPharma has a 1-year low of $16.10 and a 1-year high of $32.14.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Monday, April 20th. Oppenheimer reissued an “outperform” rating and issued a $50.00 price target (up from $44.00) on shares of ArriVent BioPharma in a report on Friday, March 6th. Truist Financial raised ArriVent BioPharma to a “strong-buy” rating in a report on Wednesday, March 25th. Citigroup raised their price target on ArriVent BioPharma from $33.00 to $45.00 and gave the company a “buy” rating in a report on Friday, April 24th. Finally, B. Riley Financial raised their price target on ArriVent BioPharma from $37.00 to $45.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ArriVent BioPharma presently has an average rating of “Moderate Buy” and a consensus target price of $43.00.

Hedge Funds Weigh In On ArriVent BioPharma

Several hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in ArriVent BioPharma by 0.7% during the fourth quarter. Wellington Management Group LLP now owns 82,278 shares of the company’s stock worth $1,655,000 after buying an additional 532 shares in the last quarter. Woodline Partners LP increased its position in ArriVent BioPharma by 0.4% during the first quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock worth $2,706,000 after buying an additional 576 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of ArriVent BioPharma by 4.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 14,743 shares of the company’s stock valued at $297,000 after purchasing an additional 585 shares during the period. BNP Paribas Financial Markets grew its position in shares of ArriVent BioPharma by 31.0% in the second quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after purchasing an additional 609 shares during the period. Finally, Legal & General Group Plc grew its position in shares of ArriVent BioPharma by 8.8% in the second quarter. Legal & General Group Plc now owns 14,790 shares of the company’s stock valued at $322,000 after purchasing an additional 1,197 shares during the period. Hedge funds and other institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.